Archive for May, 2014

cfclogo-enKALYDECO® (ivacaftor) is a prescription medicine for the treatment of cystic fibrosis in patients ages six and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. In Canada, the number of patients with this mutation is about 100. Kalydeco™, a pill taken twice a day with fat-containing food, helps the protein made by the CFTR gene function better and, as a result, improves lung function and other aspects of cystic fibrosis such as increasing weight.

On November 26, 2012, Health Canada approved Kalydeco™ for use in Canada. On March 26, 2012, it was announced that the Canadian Drug Expert Committee recommends that Kalydeco™ be listed on the formulary listing of publicly funded drug plans for the treatment of cystic fibrosis in patients age six and older who have the G551D mutation in the CFTR. Today, only a handful of CF patients in Canada who need Kalydeco™ have access through private insurance. Quebec has its own drug review process through the Institut national d’excellence en santé et en services sociaux (INESSS).



May 18 (Reuters) – The biggest risk that Middle East Respiratory Syndrome will become a global epidemic, ironically, may lie with globe-trotting healthcare workers.

So far, international health authorities have not publicly expressed concern about the flow of expatriate medical workers to and from Saudi Arabia.


Handout transmission electron micrograph shows the Middle East respiratory syndrome (MERS) coronavirus

Read Article:

Foreign doctors, nurses in Saudi Arabia could take MERS global


A tiny device placed under the skin can relieve a type of chronic snoringthat can double the risk of death, according to researchers.


The matchbox-sized implant can regulate breathing throughout the night to combat central sleep apnea, where sufferers temporarily stop breathing as they sleep. A study looking at patients with heart failure, for whom central sleep apnea can double the risk of dying, found that the device was effective at regulating breathing. (MontrealGazette)





Novel device successfully treats central sleep apnea in heart failure

New research in The FASEB Journal suggests that two receptors of leukotriene B4, BLT1 and BLT2, actually play opposite roles in inflammation, suggesting new drug targets and strategies for treatment



Inflammatory on and off switch identified for allergic asthma and COPD

High Humidity O2 Delivery



Delivering Nasal High Flow
A combination of:

  • Heated Humidifier
  • Delivery circuit that preserves humidity
  • Air/Oxygen Blender
  • Maxventuri blender (10-60l/min)
  • Standard blender with high flow flowmeter
  • Manual method with air and O2 source
  • Some ventilators with O2 therapy mode
  • Nasal Cannula Interface
  • Provides prescribed FiO2
  • Optimal Humidity Ensures Comfort and Compliance
  • Delivers low level positive airway pressure
  • Helps improve mucociliary clearance


high humidity o2 delivery

logo-ginaOn World Asthma Day, May 6, 2014, the Global Initiative for Asthma (GINA) is launching a major revision of its Global Strategy for Asthma Management and Prevention. This comprehensive and practical resource about one of the most common chronic lung diseases worldwide contains extensive citations from the scientific literature and forms the basis for other GINA documents and programs.



Content Protected Using Blog Protector By: PcDrome.
Increase your website traffic with